We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WH:NYSEWyndham Hotels & Resorts, Inc. Analysis

Data as of 2026-05-10 - not real-time

$82.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Wyndham Hotels & Resorts (WH) closed at $82.67, positioning the stock slightly below its 20‑day simple moving average of $85.02 but comfortably above the 50‑day ($81.56) and 200‑day ($80.07) levels. The 14‑day RSI sits at 48, indicating neutral momentum without clear overbought pressure. MACD shows a bearish crossover, with the line at –0.11 lagging the signal at 0.42, suggesting short‑term downside risk. Nevertheless, the broader trend remains bullish, supported by a rising volume trend and a support zone near $79.69. The stock enjoys a 2.01% dividend yield, but the payout ratio of roughly 66% raises questions about long‑term sustainability given a debt‑to‑equity ratio exceeding 590. Recent Q1 earnings beat expectations, delivering $0.96 EPS versus the consensus $0.85 and posting a 3.5% revenue increase year‑over‑year.
Despite these positives, the DCF‑derived fair value of $35.98 is dramatically lower than the current price, implying the market is pricing in a substantial premium. The forward P/E of 15.4 suggests earnings growth expectations are high, yet the trailing P/E of 32.8 signals current overvaluation. Operating margins of 37% and a robust ROE of 38% underscore strong profitability, while free cash flow remains healthy at $340 million. However, the company’s leverage—total debt of $2.65 billion against only $79 million in cash—remains a material risk factor. Analyst consensus is a “Buy” with a mean target of $100, indicating roughly 21% upside to the current level. In this context, the stock appears attractive for investors who can tolerate valuation risk and the debt load, while remaining mindful of near‑term technical headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat but price below 20‑day SMA
  • Bearish MACD crossover
  • Proximity to support at $79.69

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst target price implying 21% upside
  • Strong operating margins and cash flow
  • Forward earnings growth expectations

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Robust ROE and diversified brand portfolio
  • High leverage and overvaluation risk
  • Dividend yield sustainability contingent on debt reduction

Key Metrics & Analysis

Financial Health

Revenue Growth3.50%
Profit Margin13.40%
P/E Ratio32.8
ROE37.62%
ROA7.59%
Debt/Equity592.84
P/B Ratio13.3
Op. Cash Flow$350.0M
Free Cash Flow$340.0M

Technical Analysis

TrendBullish
RSI47.9
Support$79.69
Resistance$90.35
MA 20$85.02
MA 50$81.56
MA 200$80.07
MACDBearish
VolumeIncreasing
Fear & Greed Index90.73

Valuation

Fair Value$35.98
Target Price$100.06
Upside/Downside21.03%
GradeOvervalued
TypeBlend
Dividend Yield2.01%

Risk Assessment

Beta0.81
Volatility27.62%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.